VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 115 filers reported holding VANDA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.36 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $32,187,000 | -41.1% | 2,299,046 | -32.9% | 1.24% | -44.8% |
Q4 2016 | $54,624,000 | -4.5% | 3,424,676 | -0.3% | 2.25% | -15.5% |
Q3 2016 | $57,168,000 | -14.8% | 3,435,576 | -42.7% | 2.66% | +0.8% |
Q2 2016 | $67,103,000 | +33.9% | 5,996,691 | 0.0% | 2.64% | +23.6% |
Q1 2016 | $50,132,000 | -10.2% | 5,996,691 | 0.0% | 2.13% | -5.7% |
Q4 2015 | $55,829,000 | +3.5% | 5,996,691 | +25.3% | 2.26% | +8.4% |
Q3 2015 | $53,965,000 | -11.1% | 4,784,157 | 0.0% | 2.09% | +3.2% |
Q2 2015 | $60,711,000 | +57.9% | 4,784,157 | +15.7% | 2.02% | +62.5% |
Q1 2015 | $38,448,000 | -35.1% | 4,134,157 | -0.1% | 1.24% | -41.5% |
Q4 2014 | $59,282,000 | +163.3% | 4,139,787 | +90.9% | 2.13% | +159.4% |
Q3 2014 | $22,511,000 | +28.2% | 2,168,675 | +99.8% | 0.82% | +16.3% |
Q2 2014 | $17,560,000 | +115.4% | 1,085,301 | +116.3% | 0.71% | +112.0% |
Q1 2014 | $8,153,000 | +4.1% | 501,709 | -20.5% | 0.33% | -18.0% |
Q4 2013 | $7,834,000 | -12.8% | 631,276 | -23.0% | 0.41% | -2.9% |
Q3 2013 | $8,979,000 | – | 820,000 | – | 0.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 1,532,000 | $27,423,000 | 3.23% |
Stonepine Capital Management, LLC | 300,000 | $5,370,000 | 3.16% |
Palo Alto Investors LP | 4,155,670 | $74,386,000 | 3.13% |
GREAT POINT PARTNERS LLC | 497,531 | $8,906,000 | 1.73% |
Avoro Capital Advisors LLC | 988,270 | $17,690,000 | 1.37% |
UNIVERSITY OF NOTRE DAME DU LAC | 157,781 | $2,824,000 | 0.79% |
Birchview Capital, LP | 68,000 | $1,217,000 | 0.63% |
Cheyne Capital Management (UK) LLP | 74,000 | $1,323,000 | 0.48% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 352,604 | $6,311,000 | 0.43% |
361 CAPITAL LLC | 119,554 | $2,140,000 | 0.41% |